Johnson & Johnson (JNJ) unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

Johnson & Johnson's announcement regarding nipocalimab highlights a significant step in their Phase 2 study, showing potential to reduce SLE activity and suggesting a competitive edge in the market for FcRn blockers.

Newsquawk StaffNewswiresPublished 6 Jan 2026, 13:23 UTCOn the live feed at 13:03 UTC — 6 more headlines followed before this page went public

Newsquawk headlinesUTC

13:13

US President Trump says the US markets just hit another all time high - all of them. Thank you mister tariff, via Truth Social

13:08

Nio (NIO/9866 HK) and CATL (300750 CH) sign a battery supply agreement

13:03

Johnson & Johnson (JNJ) unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

13:02

Around 22 borrowers are looking to sell US IG bonds on Tuesday, according to Bloomberg

13:00

German HICP Prelim MM (Dec) 0.2% vs. Exp. 0.4% (Prev. -0.5%)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

The JASMINE study met the primary endpoint and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparing.

Context

The successful meeting of primary and secondary endpoints could influence investor sentiment positively, especially within the pharmaceuticals sector. Moreover, this advancement could lead to strategic discussions around future product development and regulatory pathways, impacting JNJ's overall valuation.

Equities · last 90 days

Recent headlines that moved markets

EQUITIES/8 Sept · 05:24 UTC

Saudi Energy Minister says a number of energy facilities and utilities were hit; are temporarily halting some operations.

Equity indices, after we published−0.3%

Modest downside seen across equity futures as energy prices tick higher.

EQUITIES/3 Sept · 04:54 UTC

North Korea stripped references to "peaceful unification" with South Korea from the charter of its ruling Workers' Party of Korea, according to Yonhap.

Equity indices, after we published−3.3%

EQUITIES/1 Sept · 16:17 UTC

Initial reports of an American attack on Iran, reports i24's Stein.

ES, after we published−0.2%

EQUITIES/26 Aug · 12:56 UTC

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

Market, after we published+2.6%

EQUITIES/10 Sept · 20:10 UTC

Oracle (ORCL) Q1 2027 (USD): Adj. EPS 1.92 (exp. 1.73), Revenue 19.3bln (exp. 19.13bln).

Market, after we published+10.1%

EQUITIES/10 Sept · 11:52 UTC

Yemeni Houthis are on the verge of complete control over the Bab al-Mandab Strait with control over the city of "Al-Mukha", IRNA reports.

Equity indices, after we published−0.4%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.